Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Objectives: To assess the clinical effectiveness and cost-effectiveness of bevacizumab, combined with interferon (IFN), sorafenib tosylate, sunitinib and temsirolimus in the treatment of people with advanced and/or metastatic renal cell carcinoma (RCC). Data sources: Electronic databases, including...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: J Thompson Coon, M Hoyle, C Green, Z Liu, K Welch, T Moxham, K Stein
Formato: Artigo
Lenguaje:Inglês
Publicado: NIHR Journals Library 2010-01-01
Colección:Health Technology Assessment
Materias:
bevacizumab
sorafenib-tosylate
sunitinib
temsirolimus
renal-cell-carcinoma
systematic-review
economic-evaluation
Acceso en línea:https://doi.org/10.3310/hta14020
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares